NCT01155713View on ClinicalTrials.gov

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
NeoplasmCancerTumors
Interventions
DRUG

TKI258

Trial Locations (4)

27710

Duke University Medical Center, Durham

37203

Sarah Cannon Research Institute Sarah Cannon Research Instit, Nashville

84112

University of Utah / Huntsman Cancer Institute, Salt Lake City

85258

Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY